Latest Asx Listing Rules News

K-TIG Limited is set to transform its business with a $7–10 million capital raise to acquire US-based Metal Powder Works, issuing performance-based vendor shares that an independent expert deems fair and reasonable.

Bod Science Limited reports a modest net cash inflow of $51,000 for Q2 FY2025, supported by increased customer receipts and intellectual property sales, while navigating a complex Deed of Company Arrangement and pending acquisition.

Patagonia Lithium has withdrawn its previously announced 15-year, 10,000 tonnes per annum production target, clarifying it was aspirational and not compliant with ASX Listing Rules. This retraction raises questions about the project's near-term viability and investor confidence.

Kali Metals Limited has acknowledged a delay in lodging director interest notices due to an administrative oversight, reaffirming its commitment to ASX compliance and outlining existing disclosure procedures.

Arafura Rare Earths Limited has acknowledged a breach of ASX Listing Rule 15.7 following premature media disclosure of a $200 million investment commitment from the National Reconstruction Fund Corporation. The company outlines corrective steps to prevent future compliance lapses.

Meeka Metals has responded to an ASX query regarding the timing and nature of its recent cleansing notice, confirming that the drilling results reinforce existing mineral resources without revealing new discoveries.

Great Western Exploration Limited reported a $191,000 net cash outflow from operations in the December quarter but bolstered its cash reserves to $4.74 million through a $3.6 million capital raise, maintaining a solid financial footing for ongoing exploration.

Raptis Group Limited reported a positive net cash inflow from operating activities of $54,509 for the quarter ended December 31, 2024, ending with $303,102 in cash and equivalents. The company recorded no investing or financing cash flows during the period.

RLF AgTech Ltd has retracted previously announced field trial results due to ASX compliance issues, while simultaneously reporting significant debt reduction and ongoing equity raising efforts to support its expanding Australian and Chinese operations.

InhaleRx has locked in a $38.5 million funding deal with Clendon Biotech Capital, enabling expanded Phase 2 trials for its inhaled breakthrough cancer pain and panic disorder treatments. The company also filed a key international patent, positioning itself for a faster path to FDA approval.

Australian Pacific Coal Limited has responded to ASX inquiries regarding recent unusual trading activity, confirming no undisclosed information exists and affirming compliance with listing rules.

The ASX has released its latest list of entities suspended for over three months, outlining critical deadlines for outstanding report lodgements and potential removal from the official list.